Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Xenobiotica ; 49(3): 346-362, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29543539

RESUMO

Sulfoquinovosylacylpropanediol (SQAP) is a novel potent radiosensitizer that inhibits angiogenesis in vivo and results in increased oxigenation and reduced tumor volume. We investigated the distribution, metabolism, and excretion of SQAP in male KSN-nude mice transplanted with a human pulmonary carcinoma, Lu65. For the metabolism analysis, a 2 mg (2.98 MBq)/kg of [glucose-U-14C]-SQAP (CP-3839) was intravenously injected. The injected SQAP was decomposed into a stearic acid and a sulfoquinovosylpropanediol (SQP) in the body. The degradation was relatively slow in the carcinoma tissue.1,3-propanediol[1-14C]-SQAP (CP-3635) was administered through intravenous injection of a 1 mg (3.48 MBq)/kg dose followed by whole body autoradiography of the mice. The autoradiography analysis demonstrated that SQAP rapidly distributed throughout the whole body and then quickly decreased within 4 hours except the tumor and excretion organs such as liver, kidney. Retention of SQAP was longer in tumor parts than in other tissues, as indicated by higher levels of radioactivity at 4 hours. The radioactivity around the tumor had also completely disappeared within 72 hours.


Assuntos
Glicolipídeos/farmacocinética , Radiossensibilizantes/farmacocinética , Administração Intravenosa , Animais , Autorradiografia , Cromatografia Líquida de Alta Pressão , Cromatografia Líquida , Glicolipídeos/administração & dosagem , Glicolipídeos/uso terapêutico , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Camundongos Nus , Radiossensibilizantes/administração & dosagem , Radiossensibilizantes/uso terapêutico , Espectrometria de Massas em Tandem
2.
Cancer Res ; 78(24): 6828-6837, 2018 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-30301838

RESUMO

: Hypoxic zones in solid tumors contribute to radioresistance, and pharmacologic agents that increase tumor oxygenation prior to radiation, including antiangiogenic drugs, can enhance treatment response to radiotherapy. Although such strategies have been applied, imaging assessments of tumor oxygenation to identify an optimum time window for radiotherapy have not been fully explored. In this study, we investigated the effects of α-sulfoquinovosylacyl-1,3-propanediol (SQAP or CG-0321; a synthetic derivative of an antiangiogenic agent) on the tumor microenvironment in terms of oxygen partial pressure (pO2), oxyhemoglobin saturation (sO2), blood perfusion, and microvessel density using electron paramagnetic resonance imaging, photoacoustic imaging, dynamic contrast-enhanced MRI with Gd-DTPA injection, and T2*-weighted imaging with ultrasmall superparamagnetic iron oxide (USPIO) contrast. SCCVII and A549 tumors were grown by injecting tumor cells into the hind legs of mice. Five days of daily radiation (2 Gy) combined with intravenous injection of SQAP (2 mg/kg) 30 minutes prior to irradiation significantly delayed growth of tumor xenografts. Three days of daily treatment improved tumor oxygenation and decreased tumor microvascular density on T2*-weighted images with USPIO, suggesting vascular normalization. Acute effects of SQAP on tumor oxygenation were examined by pO2, sO2, and Gd-DTPA contrast-enhanced imaging. SQAP treatment improved perfusion and tumor pO2 (ΔpO2: 3.1 ± 1.0 mmHg) and was accompanied by decreased sO2 (20%-30% decrease) in SCCVII implants 20-30 minutes after SQAP administration. These results provide evidence that SQAP transiently enhanced tumor oxygenation by facilitating oxygen dissociation from oxyhemoglobin and improving tumor perfusion. Therefore, SQAP-mediated sensitization to radiation in vivo can be attributed to increased tumor oxygenation. SIGNIFICANCE: A multimodal molecular imaging study evaluates pharmacological alteration of the tumor microenvironment to improve radiation response.


Assuntos
Imagem Molecular/métodos , Imagem Multimodal/métodos , Neoplasias/tratamento farmacológico , Neoplasias/radioterapia , Microambiente Tumoral , Células A549 , Acústica , Inibidores da Angiogênese/farmacologia , Animais , Espectroscopia de Ressonância de Spin Eletrônica , Gadolínio/química , Gadolínio DTPA/química , Glicolipídeos/farmacologia , Células Endoteliais da Veia Umbilical Humana , Humanos , Hipóxia , Imageamento por Ressonância Magnética , Camundongos , Camundongos Endogâmicos C3H , Microcirculação , Transplante de Neoplasias , Neoplasias/metabolismo , Oxigênio/química , Oxigênio/metabolismo , Fotoquímica , Tolerância a Radiação , Radioterapia
3.
J Am Chem Soc ; 135(50): 18949-56, 2013 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-24251365

RESUMO

The first total synthesis of MA026 and the identification of its candidate target protein for anti-hepatitis C virus activity are presented. MA026, a novel lipocyclodepsipeptide isolated from the fermentation broth of Pseudomonas sp. RtIB026, consists of a cyclodepsipeptide, a chain peptide, and an N-terminal (R)-3-hydroxydecanoic acid. The first subunit, side chain 2, was prepared by coupling fatty acid moiety 4 with tripeptide 5. The key macrocyclization of the decadepsipeptide at L-Leu(10)-D-Gln(11) provided the second subunit, cyclodepsipeptide 3. Late-stage condensation of the two key subunits and final deprotection afforded MA026. This convergent, flexible, solution-phase synthesis will be invaluable in generating MA026 derivatives for future structure-activity relationship studies. An infectious hepatitis C virus (HCV) cell culture assay revealed that MA026 suppresses HCV infection into host hepatocytes by inhibiting the entry process in a dose-dependent manner. Phage display screening followed by surface plasmon resonance (SPR) binding analyses identified claudin-1, an HCV entry receptor, as a candidate target protein of MA026.


Assuntos
Antivirais/síntese química , Antivirais/farmacologia , Depsipeptídeos/síntese química , Depsipeptídeos/farmacologia , Hepacivirus/efeitos dos fármacos , Fermentação
4.
Anticancer Res ; 30(11): 4397-404, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21115885

RESUMO

AIM: The purpose of this study was to examine the effects of combined treatment with a specific type of sulfoglycolipid, α-sulfoquinovosylmonoacylglycerol (α-SQMG), and X-irradiation (XRT) on the remodeling of tumor microenvironments. MATERIALS AND METHODS: A human colon cancer cell line, SW480, was used in this study. The cells were injected subcutaneously into nude mice and the resulting tumors were treated with α-SQMG that was injected intravenously and/or X-irradiation (XRT). The tumor volumes were monitored and the microenvironments of the treated tumors were immunohistochemically analyzed for angiogenesis, pericyte recruitment, and hypoxic fractions using markers for CD31, collagen IV, α-Sma, and pimonidazole. RESULTS: The combined treatment with α-SQMG (five daily injections from days zero to four) and X-irradiation (two fractions on days zero and three) synergistically enhanced the radioresponse of tumor growth in vivo, whereas α-SQMG treatment alone had no effect. The tumor vessel density was significantly decreased at days 10 and 20 after initiating the combined treatment. On day 20, areas with overlapping CD31 and collagen IV expression were rarely observed, suggesting that the normal structures of most tumor vessels had collapsed. α-Sma staining was significantly increased and pimonidazole staining was significantly reduced at 24 and 72 h, but not 6 h, after the first combined treatment. CONCLUSION: The combined treatment induced remodeling of the microenvironments in SW480 tumors, which might contribute to the radiosensitization to the second irradiation.


Assuntos
Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/radioterapia , Glicolipídeos/farmacologia , Radiossensibilizantes/farmacologia , Microambiente Tumoral/efeitos dos fármacos , Microambiente Tumoral/efeitos da radiação , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Adenocarcinoma/radioterapia , Animais , Neoplasias do Colo/patologia , Terapia Combinada , Humanos , Masculino , Camundongos , Camundongos Nus , Neovascularização Patológica/tratamento farmacológico , Neovascularização Patológica/radioterapia , Células Tumorais Cultivadas , Terapia por Raios X , Ensaios Antitumorais Modelo de Xenoenxerto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...